# Elutia Inc. Class A Common Stock (ELUT)

> Elutia Inc. Class A Common Stock (ELUT) trades at $0.8200 (-6.69%) as of 4:10:03 PM EST on Nov 13, 2026, +3.96% over the past month. Market cap is $39.02M, with 1.0 days to cover in short interest.

Canonical: https://massive.com/quote/elut
Data as of: 2026-11-13T21:10:03.945Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.8200** -0.06 (-6.69%)
As of 4:10:03 PM EST on Nov 13, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Elutia Inc. Class A Common Stock (ELUT) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -6.69% |
| 1W | -2.08% |
| 1M | +3.96% |
| YTD | +18.38% |
| 1Y | +9.99% |
| 52-wk range | $0.50 – $1.39 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for ELUT: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.79 – $0.88 |
| Open | $0.85 |
| Prev close | $0.88 |
| Volume | 50.44K |
| Market cap | $39.02M |
| Shares out | 44.29M |

## Valuation and profitability ratios

Valuation and profitability ratios for Elutia Inc. Class A Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 0.72 |
| P/S | 3.93 |
| P/B | 2.55 |
| P/FCF | — |
| ROE | 354.9% |
| ROA | 112.9% |
| Debt/Equity | 0.53 |
| Div yield | 0.00% |

As of Nov 12, 2026

## Insider trading

[Elutia Inc. Class A Common Stock (ELUT) insider trading](https://massive.com/quote/elut/insider-trading.md): open-market Form 4 buys and sells by Elutia Inc. Class A Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Elutia Inc. Class A Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Elutia Inc. (the "Company" or "Elutia") issued a press release announcing its results for the third quarter ended September 30, 2026.”
- Aug 21, 2026 · Credit facility
  “Also in connection with the completion of the sale of the SimpliDerm Business assets, the Company amended its Loan and Security Agreement dated August 11, 2026 with Avenue Venture Opportunities Fund II, L.P., as agent, and the lenders party thereto, to release the lien on the assets.”
- Aug 7, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On August 6, 2026, Elutia Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's Class A common stock was below $1.00 per share, which is the minimum closing bid price required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Company was provided a compliance period of 180 calendar days from the date of the Notice, or until February 2, 2027, to regain compliance with the Minimum Bid Price requirement.”
- Jul 20, 2026 · Business line exit
  “The assets of the SimpliDerm Business constitute substantially all of the assets currently held in Elutia's Women's Health segment. Cellution Biologics will purchase from the Company substantially all of the assets related to the Company's business of commercializing, manufacturing, distributing, selling and/or marketing human acellular dermis (hADM) products for use in the field of breast reconstruction under the SimpliDerm® brand.”
- Jun 16, 2026 · Equity compensation grant
  “The First Amendment: (i) increased the number of shares authorized for issuance of awards under the 2020 Plan by an additional 3,000,000 shares of the Company's Class A common stock; (2) extended the annual increase of shares of the Company's Class A common stock authorized under the 2020 Plan through January 1, 2036 (the tenth January 1 after the Amendment Date); and (3) extended the termination date of the 2020 Plan to the tenth anniversary of the Amendment Date.”

## ELUT short interest

How heavily ELUT is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.0 |
| Short interest | 33.66K |
| Avg volume | 70.79K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ELUT news

The latest news and headlines about Elutia Inc. Class A Common Stock (ELUT).

- [Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://www.globenewswire.com/news-release/2026/03/13/3255424/0/en/Elutia-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html) · GlobeNewswire Inc. · Mar 13, 2026 · neutral sentiment
- [Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million](https://www.benzinga.com/pressreleases/25/10/g47965974/elutia-announces-closing-of-bioenvelope-business-sale-to-boston-scientific-corporation-for-88-mill) · Benzinga · Oct 1, 2025 · positive sentiment
- [Zacks.com featured highlights BRC, Costamare and Elutia](https://www.zacks.com/stock/news/2294092/zackscom-featured-highlights-brc-costamare-and-elutia) · Zacks Investment Research · Jun 27, 2024
- [3 Best Breakout Stocks Worth a Buy for Attractive Returns](https://www.zacks.com/stock/news/2293436/3-best-breakout-stocks-worth-a-buy-for-attractive-returns) · Zacks Investment Research · Jun 26, 2024
- [Elutia Announces $13.26 Million Registered Direct Offering](https://www.globenewswire.com/news-release/2024/06/17/2899620/0/en/Elutia-Announces-13-26-Million-Registered-Direct-Offering.html) · GlobeNewswire Inc. · Jun 17, 2024

## About Elutia Inc. Class A Common Stock

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 26 |
| Listed | Oct 8, 2020 |

[Company website](https://www.elutia.com)

## FAQ

### What is the Elutia Inc. Class A Common Stock (ELUT) stock price today?

Elutia Inc. Class A Common Stock (ELUT) is trading at $0.8200 (-6.69% on the day) as of 4:10:03 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Elutia Inc. Class A Common Stock?

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients.

### What is the short interest in ELUT?

As of Oct 30, 2026, ELUT has 33.66K shares short and 1.0 days to cover.

### What exchange is ELUT listed on?

Elutia Inc. Class A Common Stock (ELUT) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time ELUT quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ELUT`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Elutia Inc. Class A Common Stock (ELUT) insider trading](https://massive.com/quote/elut/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms